Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amgen (AMGN)
NASDAQ:AMGN
Holding AMGN?
Track your performance easily
AMGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$253.30 - $346.85
Previous CloseN/A
Volume614.18K
Average Volume (3M)3.64M
Market Cap
$143.58B
Enterprise Value$226.03B
Total Cash (Recent Filing)$38.09B
Total Debt (Recent Filing)$30.19B
Price to Earnings (P/E)34.4
Beta0.46
Next Earnings
Feb 04, 2025EPS Estimate
5.09Next Dividend Ex-Date
Feb 14, 2025Dividend Yield3.37%
Share Statistics
EPS (TTM)7.81
Shares Outstanding537,532,700
10 Day Avg. Volume3,100,160
30 Day Avg. Volume3,642,448
Standard Deviation0.07
R-Squared0.17
Alpha-0.00010
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.44
Price to Cash Flow (P/CF)10.10
P/FCF Ratio9.00
Enterprise Value/Market Cap1.57
Enterprise Value/Revenue6.95
Enterprise Value/Gross Profit11.45
Enterprise Value/Ebitda16.76
Forecast
1Y Price Target
$337.06Price Target Upside25.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
Amgen News
Bulls Say, Bears Say
Bulls Say
Clinical Trials And InnovationThe likelihood of success for AMGN's olpasiran candidate in its clinical trial is projected to be high, which may boost expectations.
Financial Performance And Market PositionAmgen is on track to double biosimilar sales by the end of the decade with Amjevita and Pavblu being of focus for investors.
Product Development And Market ExpansionMariTide data firmly establishes Amgen as a competitor in obesity and diabetes indications, showing compelling weight loss in both indications.
Bears Say
Market CompetitionCommercial dynamics in the GLP-1/obesity space make it difficult for late entrants like MariTide to capture meaningful market share.
Product EfficacyThe efficacy of MariTide is unlikely to be better than LLY's Tirzepatide and future next-gen options in the diabesity pipeline.
Revenue ExpectationsThe MariTide sales estimate for 2031 has been reduced, indicating lower expected revenues.
---
Ownership Overview
0.18% Insiders
21.27% Mutual Funds
0.77% Other Institutional Investors
49.74% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AMGN FAQ
What was Amgen’s price range in the past 12 months?
Amgen lowest stock price was $253.30 and its highest was $346.85 in the past 12 months.
What is Amgen’s market cap?
Amgen’s market cap is $143.58B.
When is Amgen’s upcoming earnings report date?
Amgen’s upcoming earnings report date is Feb 04, 2025 which is in 17 days.
How were Amgen’s earnings last quarter?
Amgen released its earnings results on Oct 30, 2024. The company reported $5.58 earnings per share for the quarter, beating the consensus estimate of $5.274 by $0.306.
Is Amgen overvalued?
According to Wall Street analysts Amgen’s price is currently Undervalued.
Does Amgen pay dividends?
Amgen pays a Quarterly dividend of $9 which represents an annual dividend yield of 3.37%. See more information on Amgen dividends here
What is Amgen’s EPS estimate?
Amgen’s EPS estimate is 5.09.
How many shares outstanding does Amgen have?
Amgen has 537,532,700 shares outstanding.
What happened to Amgen’s price movement after its last earnings report?
Amgen reported an EPS of $5.58 in its last earnings report, beating expectations of $5.274. Following the earnings report the stock price went up 1.463%.
Which hedge fund is a major shareholder of Amgen?
Among the largest hedge funds holding Amgen’s share is PRIMECAP Management Co. It holds Amgen’s shares valued at 5B.
---
Amgen Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$337.06 (25.10% Upside)
$337.06 (25.10% Upside)
Blogger Sentiment
Bullish
AMGN Sentiment 89%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 331.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 4.5%
Last 30 Days ▲ 4.5%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.53%
12-Months-Change
Fundamentals
Return on Equity
55.72%
Trailing 12-Months
Asset Growth
0.39%
Trailing 12-Months
Company Description
Amgen
Founded in 1980, California-based Amgen, Inc. is one of the world's leading biotechnology companies, which is engaged in the discovery, development, manufacture and marketing of human therapeutics. It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.
---
AMGN Company Deck
---
AMGN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong performance across key product segments, particularly in oncology and rare diseases, with substantial revenue growth and expansion plans. However, there were noted challenges with declining sales in certain legacy products like Enbrel and Otezla. Overall, the sentiment was positive with a focus on continued growth and innovation.Read More>---
AMGN Revenue Breakdown
14.36% Prolia
13.11% Enbrel
7.76% Otezla
7.49% XGEVA
57.27% Other
---
AMGN Stock 12 Month Forecast
Average Price Target
$337.06
▲(25.10% Upside)
Technical Analysis
Gilead Sciences
―
Biogen
―
Regeneron
―
Vertex Pharmaceuticals
―
Bristol-Myers Squibb
―
Merck & Company
―
Best Analysts Covering AMGN
1 Year
1 Year Success Rate
22/34 ratings generated profit
1 Year Average Return
+10.08%
reiterated a buy rating 2 months ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 64.71% of your transactions generating a profit, with an average return of +10.08% per trade.
---